Protalix BioTherapeutics Inc. share price logo

Protalix BioTherapeutics Inc.

NASDAQ: PLX

Small Cap

$2.22

+0.20

(+9.90%)

as on

Protalix BioTherapeutics Inc. Stock Performance

as on June 19, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $2.01
    $2.23
    downward going graph

    9.46%

    Downside

    0.45%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.32
    $3.19
    downward going graph

    40.54%

    Downside

    43.69%

    Upside

    downward going graph

Protalix BioTherapeutics Inc. share price movements today

Previous Close
$2.02
Open
$2.04
Volume
2.5M
Day's Low - High
$2.01 - $2.23
52 Week Low - High
$1.32 - $3.19

Protalix BioTherapeutics Inc. Historical Returns

1 Month Return
+ 16.84 %
3 Month Return
-0.45 %
1 Year Return
+ 58.57 %
3 Year Return
+ 3.26 %
5 Year Return
0 %

Protalix BioTherapeutics Inc. Stock Fundamentals & Key Indicators

Check Protalix BioTherapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$162.8M

EPS (TTM)

0.195

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.01%

PE Ratio (TTM)

10.63

Industry PE ratio

-3.7464601769911505

PEG Ratio

-0.1

EBITDA

21.3M

Revenue (TTM)

76.4M

Profit Margin

20.07%

Return On Equity TTM

27.27%

Protalix BioTherapeutics Inc. Stock Valuation

Track how Protalix BioTherapeutics Inc. P/E has moved over time to understand its valuation trends.

Protalix BioTherapeutics Inc. in the last 5 years

  • Overview

  • Trends

Lowest (-15.73x)

December 31, 2025

Industry (-3.75x)

June 19, 2026

Today (10.63x)

June 19, 2026

Highest (119.12x)

June 30, 2023

LowHigh

Today’s Price to Earnings Ratio: 10.63x

Protalix BioTherapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Protalix BioTherapeutics Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Protalix BioTherapeutics Inc. image
Protalix BioTherapeutics Inc.
BUY$162.8MNA10.6320.07%NA
Alnylam Pharmaceuticals Inc. image
Alnylam Pharmaceuticals Inc.
BUY$37.7B57.21%71.2112.55%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$116.5B140.42%27.2235.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$63.7B13.39%14.8529.65%0.58%

Stock Returns calculator for Protalix BioTherapeutics Inc. Stock including INR - Dollar returns

The Protalix BioTherapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Protalix BioTherapeutics Inc. investment value today

Current value as on today

₹1,72,211

Returns

₹72,211

(+72.21%)

Returns from Protalix BioTherapeutics Inc. Stock

₹58,571 (+58.57%)

Dollar Impact

₹13,639 (+13.64%)

Analyst Recommendation on Protalix BioTherapeutics Inc. Stock

Based on 5 analysts

BUY

80.00%

Buy

20.00%

Hold

0.00%

Sell

Based on 5 analysts, 80% of analysts recommend a 'BUY' rating for Protalix BioTherapeutics Inc.. Average target price of $11

Protalix BioTherapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Protalix BioTherapeutics Inc..

What analysts predicted

79.82%UPSIDE

Target Price

$11

Current Price

$2.22

Analyzed by

5 Analysts

Target

$11.00

Protalix BioTherapeutics Inc. target price $11, a slight upside of 79.82% compared to current price of $2.22. According to 5 analysts rating.

Indian Investors' Interest in Protalix BioTherapeutics Inc. Stock

Search interest for Protalix BioTherapeutics Inc. Stock has decreased by -33% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-33% versus previous 30 day period

Protalix BioTherapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
10
3
13
17
18
10
15
17
9
33
Gross Profit
1
1
4
9
14
1
9
9
4
29
Operating Income
-5
-4
-2
3
7
-4
1
2
-4
21
EBITDA
-5
-4
-1
4
7
-3
1
2
-4
21
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-6
-4
-2
3
7
-3
0
2
-4
21
Income Tax Expense
0
0
0
0
0
0
0
0
0
2
Net Income
-6
-4
-2
3
6
-3
0
2
-5
18
Net Profit Margin
-57.64%
-122.60%
-16.35%
18.02%
35.65%
-35.79%
1.05%
13.19%
-60.34%
54.27%

Protalix BioTherapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
9
21
34
54
62
38
47
65
53
52
Gross Profit
0
5
24
43
52
22
28
42
29
25
Operating Income
-33
-34
-19
-10
2
-20
-13
10
3
-5
EBITDA
-23
-71
-17
-8
4
-18
-10
12
6
-2
Interest Expense
4
9
7
7
9
7
2
3
1
1
Depreciation
-
1
1
1
1
1
1
1
1
1
Income Before Tax
-29
-83
-26
-18
-6
-27
-14
8
4
-5
Income Tax Expense
10
7
0
7
8
6
0
0
1
0
Net Income
-29
-83
-26
-18
-6
-27
-14
8
2
-6
Net Profit Margin
-319.22%
-395.86%
-77.27%
-33.42%
-10.37%
-71.92%
-31.33%
12.69%
5.49%
-12.52%

Protalix BioTherapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-4
-2
3
6
-3
0
2
1
18
Operating Cash Flow
4
-3
4
3
-5
-5
-3
2
22
Investing Cash Flow
0
0
20
-15
0
0
0
-1
4
Financing Cash Flow
-
-
-20
3
5
4
9
0
0
Change in Cash
3
-3
4
-7
0
-1
-4
1
26

Protalix BioTherapeutics Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-85
-26
-18
-6
-27
-14
8
2
-6
Operating Cash Flow
-9
-7
-19
-26
-10
-25
-1
8
-11
Investing Cash Flow
-1
0
0
-19
18
-5
-16
4
-2
Financing Cash Flow
-1
-4
46
46
12
8
24
-16
9
Change in Cash
-12
-13
-20
0
20
-21
6
-3
-4

Insights on Protalix BioTherapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 9.12M → 33.75M (in $), with an average increase of 73.0% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -5.50M → 18.31M (in $), with an average increase of 130.1% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, PLX stock has moved up by 6.2%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, PLX has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, PLX has outperformed top 5 stocks with highest market-cap in its industry

About Protalix BioTherapeutics Inc.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
OrganisationProtalix BioTherapeutics Inc.
Headquarters2 University Plaza, Hackensack, NJ, United States, 07601
IndustryBiotechnology
CEOMr. Dror Bashan
E-voting on sharesClick here to vote

Key Management of Protalix BioTherapeutics Inc.

Name

Title

Mr. Dror Bashan

President, CEO & Director

Mr. Gilad Mamlok

Senior VP, CFO Treasurer & Secretary

Mr. Yaron Naos B.Sc., MBA

SVP & COO

Ms. Yael Fellous

Vice President of Human Resources

FAQs

What is Protalix BioTherapeutics Inc. share price today?

Protalix BioTherapeutics Inc. share price today is $2.22 as on at the close of the market. Protalix BioTherapeutics Inc. share today touched a day high of $2.23 and a low of $2.01.

What is the 52 week high and 52 week low for Protalix BioTherapeutics Inc. share?

Protalix BioTherapeutics Inc. share touched a 52 week high of $3.19 on and a 52 week low of $1.32 on . Protalix BioTherapeutics Inc. stock price today i.e. is closed at $2.22,which is 30.41% down from its 52 week high and 68.18% up from its 52 week low.

What is Protalix BioTherapeutics Inc.'s market capitalisation today?

Protalix BioTherapeutics Inc. market capitalisation is $0.00T as on .

How to invest in Protalix BioTherapeutics Inc. Stock (PLX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Protalix BioTherapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Protalix BioTherapeutics Inc. Shares that will get you 0.6757 shares as per Protalix BioTherapeutics Inc. share price of $2.22 per share as on June 19, 2026 at 8:45 am IST.

What is the minimum amount required to buy Protalix BioTherapeutics Inc. Stock (PLX) from India?

Indian investors can start investing in Protalix BioTherapeutics Inc. (PLX) shares with as little as ₹94.31 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹943.10 in Protalix BioTherapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Protalix BioTherapeutics Inc. share’s latest price of $2.22 as on June 19, 2026 at 8:45 am IST, you will get 4.5045 shares of Protalix BioTherapeutics Inc.. Learn more about fractional shares .